September 13, 2016
LA JOLLA—The Salk Institute Board of Trustees welcomes its newest trustee, Eric S. Sagerman. Chaired by Irwin M. Jacobs, the 33-member Salk board helps drives the strategic direction of the Institute founded by polio vaccine pioneer Jonas Salk in 1960.
A strategic advisor to companies across multiple industries around the globe, Sagerman brings broad financial, technology and health care experience to his new role at Salk. Most recently, from 2009 to 2011, he was CEO and president of the medical records company Universata, which he restructured and orchestrated its successful sale. From 1999 to 2008, Sagerman was a managing director and Head of Strategy and Strategic Marketing for Allianz Global Investors—Munich, a successor firm to Nicholas Applegate Capital Management, where he was a managing director and member of the executive committee.
In his 16 years with American Express, Sagerman served in a number of marketing and business management posts, both domestically and internationally. As senior vice president, he was involved in many growth and restructuring initiatives, including launching the Global Network Services business, the Corporate Card business and the Centurion “Black” Card.
Sagerman currently serves on the board of Teach for America, San Diego, and is a member of the Salk Institute Investment Committee. He is a former board member of RAS Asset Management in Milan, Italy.
Sagerman earned a BA in economics from Tufts University and an MBA from the Amos Tuck School, Dartmouth College. He and his wife, Jane, live in La Jolla, California.
Büro für Kommunikation
Telefon: (858) 453-4100
press@salk.edu
Das Salk Institute ist ein unabhängiges, gemeinnütziges Forschungsinstitut, das 1960 von Jonas Salk, dem Entwickler des ersten sicheren und wirksamen Polio-Impfstoffs, gegründet wurde. Die Aufgabe des Instituts besteht darin, grundlegende, kooperative und risikofreudige Forschung voranzutreiben, die sich mit den dringendsten Herausforderungen der Gesellschaft befasst, darunter Krebs, Alzheimer und die Gefährdung der Landwirtschaft. Diese Grundlagenforschung bildet die Basis für alle translationalen Bemühungen und führt zu Erkenntnissen, die neue Medikamente und Innovationen weltweit ermöglichen.
